• Home
  • About us
  • Our products
  • Your health
  • Responsibility
  • In the community
  • Research & development
  • Investors
  • Media centre
  • Careers

Investors

This section of our website contains essential information GSK's financial performance. View and download our results and reports, use our share price tools to monitor your investments, and keep up-to-date with the latest news and events.

Investor news

2 February 2006
FDA approves new formulation of Imitrex® (sumatriptan succinate) injection

More news

Presentations and webcasts

8 February 2006
2005 Q4 results
2005 fourth quarter results will be announced on Wednesday 8 February 2006. Full details of the results announcement and the analyst presentation will be available to view and download.

Webcast registration and test
Find out more

Share price

LSE
1448.00p
+14.00

4 Feb 2006 closed
NYSE
50.97
+0.07

4 Feb 2006 closed
15 minute delayed share price from the London Stock Exchange provided by
Hemscott Group Limited
Terms of use

Share price analysis
Q3 results highlights
21.3p earnings per share up 16% in line with earnings guidance.
20% increase in vaccine sales driven by strong strategic investment and strategy.
 

Product pipeline

Building the best product pipeline in the industry
We aim to create the best product pipeline in the industry for the benefit of patients, consumers and society.

Our R&D; organisation measures productivity by the number and innovation of the products it creates, and also by the commercial value of the products.

Find out more